{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T16:34:08Z","timestamp":1775493248818,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.bulcan.2023.04.017","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T09:53:22Z","timestamp":1684230802000},"page":"836-843","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ad\u00e9nosarcomes mull\u00e9riens de l\u2019ut\u00e9rus\u00a0\u2013\u00a0r\u00e9f\u00e9rentiels de prise en charge du GSF-GETO\/NETSARC+ et du groupe TMRG"],"prefix":"10.1016","volume":"110","author":[{"given":"Andy","family":"Karabajakian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Genestie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Meeus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Guyon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Llacer Moscardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Croce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Duffaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Pautier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2023.04.017_bib0005","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11912-016-0552-7","article-title":"Uterine Adenosarcoma: a review","volume":"18","author":"Nathenson","year":"2016","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0010","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2559.2009.03231.x","article-title":"Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970\u00a0to 2000\u00a0including 419\u00a0patients","volume":"54","author":"Abeler","year":"2009","journal-title":"Histopathology"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0015","series-title":"Female genital tumours","article-title":"Adenosarcoma of uterine corpus","author":"Howitt Brooke","year":"2020"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0020","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ygyno.2009.09.023","article-title":"Uterine sarcomas: a review","volume":"116","author":"D\u2019Angelo","year":"2010","journal-title":"Gynaec Oncol"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0025","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ygyno.2014.10.022","article-title":"Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence","volume":"135","author":"Carroll","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2023.04.017_bib0030","doi-asserted-by":"crossref","first-page":"e0246958","DOI":"10.1371\/journal.pone.0246958","article-title":"Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network","volume":"16","author":"De Pinieu","year":"2021","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.bulcan.2023.04.017_bib0035","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ygyno.2010.07.001","article-title":"Long-term outcome and natural history of uterine adenosarcomas","volume":"119","author":"Arend","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0040","first-page":"201219","article-title":"Uterine adenosarcoma in a patient with history of breast cancer and long-term tamoxifen consumption","volume":"19","author":"Akhavan","year":"2012","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0045","first-page":"95","article-title":"A case of synchronous relapse of breast cancer and uterine m\u00fcllerian adenosarcoma post tamoxifen in a premenopausal woman","volume":"29","author":"Farhat","year":"2008","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0050","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00004347-200104000-00004","article-title":"Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types","volume":"20","author":"Stern","year":"2001","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0055","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/ol.2012.690","article-title":"Identification of multiple pathways involved in the malignant transformation of endometriosis (Review)","volume":"4","author":"Higashiura","year":"2012","journal-title":"Oncol Lett"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0060","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/00000478-200210000-00001","article-title":"Mesodermal (m\u00fcllerian) adenosarcoma of the ovary: a clinicopathologic analysis of 40\u00a0cases and a review of the literature","volume":"26","author":"Eichhorn","year":"2002","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.bulcan.2023.04.017_bib0065","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2463\/mrms.10.251","article-title":"MR imaging of uterine adenosarcoma: case report and literature review","volume":"10","author":"Yoshizako","year":"2011","journal-title":"Magn Reson Med Sci"},{"issue":"3","key":"10.1016\/j.bulcan.2023.04.017_bib0070","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ygyno.2009.07.033","article-title":"Extragenital adenosarcoma: a case report, review of the literature, and management discussion","volume":"115","author":"Huang","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0075","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0046-8177(90)90198-E","article-title":"Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100\u00a0cases with a review of the literature","volume":"21","author":"Clement","year":"1990","journal-title":"Hum Pathol"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0080","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00004347-199204000-00001","article-title":"Adenosarcoma of the uterus: a gynecologic oncology group clinicopathologic study of 31\u00a0cases","volume":"11","author":"Kaku","year":"1992","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0085","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/jso.2930510117","article-title":"Mullerian adenosarcoma of the uterus with sarcomatous overgrowth","volume":"51","author":"Hallak","year":"1992","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0090","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1097\/PAS.0b013e318161d1be","article-title":"Mullerian adenosarcomas: an immunophenotypic analysis of 35\u00a0cases","volume":"32","author":"Soslow","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0095","doi-asserted-by":"crossref","first-page":"27888","DOI":"10.1097\/PAS.0b013e318181a80d","article-title":"Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55\u00a0cases challenging the existence of adenofibroma","volume":"33","author":"Gallardo","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0100","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.ejca.2009.06.017","article-title":"\u03b2-Catenin expression in uterine sarcomas and its relation to clinicopathological parameters","volume":"45","author":"Kildal","year":"2009","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.bulcan.2023.04.017_bib0105","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1097\/PAS.0000000000000907","article-title":"High-grade M\u00fcllerian adenosarcoma: genomic and clinicopathologic characterization of a distinct neoplasm with prevalent TP53\u00a0pathway alterations and aggressive behavior","volume":"41","author":"Hodgson","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0110","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/path.4442","article-title":"Targeted genomic analysis of Mullerian adenosarcoma","volume":"235","author":"Howitt","year":"2015","journal-title":"J Pathol"},{"issue":"6","key":"10.1016\/j.bulcan.2023.04.017_bib0115","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/s41379-019-0436-0","article-title":"Significantly greater prevalence of DICER1\u00a0alterations in uterine embryonal rhabdomyosarcoma compared to adenosarcoma","volume":"33","author":"de Kock","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0120","doi-asserted-by":"crossref","DOI":"10.1177\/1179554918782477","article-title":"A single-centre experience on the management of adenosarcoma: a successful report of an integrated medical and surgical approach","volume":"12","author":"Nannini","year":"2018","journal-title":"Clin Med Insights Oncol"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0125","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1159\/000494067","article-title":"Uterine adenosarcoma","volume":"41","author":"Ulrich","year":"2018","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0130","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1097\/IGC.0000000000000239","article-title":"Gynecologic cancer intergroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract","volume":"24","author":"Friedlander","year":"2014","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2023.04.017_bib0135","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/gyno.2001.6334","article-title":"Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival","volume":"83","author":"Krivak","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0140","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ygyno.2012.12.036","article-title":"Management of uterine adenosarcomas with and without sarcomatous overgrowth","volume":"129","author":"Tanner","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0145","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12957-017-1137-0","article-title":"Feasibility of uterine preservation in the management of early-stage uterine adenosarcomas: A single institute experience","volume":"15","author":"Lee","year":"2017","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0150","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ygyno.2017.01.012","article-title":"Significance of lymph node metastasis on survival of women with uterine adenosarcoma","volume":"144","author":"Machida","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0155","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00004347-200201000-00012","article-title":"Primary peritoneal mullerian adenosarcoma with sarcomatous overgrowth associated with endometriosis: a case report","volume":"21","author":"Dincer","year":"2002","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0160","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1080\/14737140.2018.1518136","article-title":"Prognostic factors for uterine adenosarcoma: a review","volume":"18","author":"Nathenson","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0165","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1006\/gyno.2002.6585","article-title":"Use of medroxyprogesterone acetate in the treatment of m\u00fcllerian adenosarcoma: a case report","volume":"85","author":"Hines","year":"2002","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0170","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1111\/IGC.0b013e3181a84062","article-title":"Oral progesterone treatment in a young woman with m\u00fcllerian adenosarcoma whose ovary was preserved: a case report","volume":"20","author":"Lee","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.wneu.2011.03.035","article-title":"Intracranial meningiomas in patients with uterine sarcoma treated with long-term megestrol acetate therapy","volume":"76","author":"Gruber","year":"2011","journal-title":"World Neurosurg"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0180","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1186\/2193-1801-2-618","article-title":"Therapeutic effect of dienogest on adenosarcoma arising from endometriosis: a case report","volume":"2","author":"Tasaka","year":"2013","journal-title":"Springerplus"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0185","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3892\/mco.2014.272","article-title":"A retrospective study on combination therapy with ifosfamide, adriamycin and cisplatin for progressive or recurrent uterine sarcoma","volume":"2","author":"Yamagami","year":"2014","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0190","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S0090-8258(02)00093-8","article-title":"A case of M\u00fcllerian adenosarcoma of the uterus treated with liposomal doxorubicin","volume":"88","author":"del Carmen","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0195","first-page":"542","article-title":"Activity of pegylated liposomal doxorubicin for extragenital mullerian adenosarcoma with sarcomatous overgrowth: a case report and a review of the literature","volume":"32","author":"Maeda","year":"2011","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0200","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/annonc\/mdr299","article-title":"Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the axtell regimen","volume":"23","author":"Verschraegen","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0205","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s12032-013-0501-3","article-title":"Clinical benefit of trabectedin in uterine adenosarcoma","volume":"30","author":"Schroeder","year":"2013","journal-title":"Med Oncol"},{"key":"10.1016\/j.bulcan.2023.04.017_bib0210","doi-asserted-by":"crossref","first-page":"4680273","DOI":"10.1155\/2017\/4680273","article-title":"Treatment of recurrent or metastatic uterine adenosarcoma","volume":"2017","author":"Nathenson","year":"2017","journal-title":"Sarcoma"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123002126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123002126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:37:48Z","timestamp":1757792268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455123002126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":42,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0007455123002126"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.04.017","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ad\u00e9nosarcomes mull\u00e9riens de l\u2019ut\u00e9rus\u00a0\u2013\u00a0r\u00e9f\u00e9rentiels de prise en charge du GSF-GETO\/NETSARC+ et du groupe TMRG","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}